Adjuvant interferon alfa treatment for patients with malignant melanoma stimulates transporter proteins associated with antigen processing and proteasome activator 28

Lancet Oncol. 2004 Apr;5(4):250. doi: 10.1016/S1470-2045(04)01429-9.
No abstract available

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 2
  • ATP Binding Cassette Transporter, Subfamily B, Member 3
  • ATP-Binding Cassette Transporters / biosynthesis*
  • ATP-Binding Cassette Transporters / pharmacology
  • Antineoplastic Agents / pharmacology*
  • Chemotherapy, Adjuvant
  • Humans
  • Immunoblotting
  • Immunohistochemistry
  • Interferon-alpha / pharmacology*
  • Leukocytes, Mononuclear
  • Melanoma / drug therapy*
  • Melanoma / genetics*
  • Muscle Proteins / pharmacology*
  • Proteasome Endopeptidase Complex
  • Proteins / pharmacology*
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / genetics*
  • Up-Regulation

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 2
  • ATP Binding Cassette Transporter, Subfamily B, Member 3
  • ATP-Binding Cassette Transporters
  • Antineoplastic Agents
  • Interferon-alpha
  • Muscle Proteins
  • PSME1 protein, human
  • Proteins
  • TAP1 protein, human
  • TAP2 protein, human
  • Proteasome Endopeptidase Complex